Levact

Bendamustine, the active ingredient in Levact, is an alkylating agent presented as an intravenous solution for intravenous use. It is employed in the treatment of chronic lymphocytic leukemia and non‑Hodgkin lymphoma in adult patients and works by interfering with DNA replication in malignant cells.

GNH USA supplies Levact as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Levact (bendamustine) is used in hematologic malignancies that involve abnormal B‑cell proliferation.

Chronic lymphocytic leukemia: induces remission and disease control in adult patients. Non‑Hodgkin lymphoma: provides tumor reduction and prolongs progression‑free survival. Mantle cell lymphoma: offers therapeutic benefit in relapsed or refractory disease.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Nausea and vomiting - Fatigue - Decreased blood cell counts (neutropenia, anemia, thrombocytopenia) - Fever or chills

Serious or Rare Side Effects: - Severe infections due to immunosuppression - Pulmonary toxicity such as interstitial pneumonitis - Secondary malignancies

Prior to initiating therapy, several safety considerations should be observed.

Monitor blood counts: perform regular complete blood count assessments. Assess hepatic function: evaluate liver enzymes before and during treatment. Evaluate renal function: adjust therapy if significant impairment is present. Avoid in patients with known hypersensitivity to bendamustine or its excipients. Use effective contraception: advise women of childbearing potential to avoid pregnancy. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Bendamustine may interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Concurrent strong CYP3A4 inhibitors (e.g., ketoconazole) may increase toxicity. - Co‑administration with other myelosuppressive agents can exacerbate bone‑marrow suppression. - Use with live vaccines is contraindicated due to immunosuppression risk.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin) may reduce efficacy. - Anticoagulants may increase bleeding tendency. - CYP2C9 substrates could have altered plasma levels requiring dose adjustment.